MUCOPOLYSACCHARIDOSIS-MPS

RARE-DISEASE

MPSI – Rheumatology Case Study

<p>By simulating a real-life Scenario this case study developed to increase the awareness of MPS I, by highlighting familiar symptoms that suggest the possibility of an unfamiliar underlying metabolic disease for Rheumatologist specialty.</p>

<h2>Are you interested in knowing more about this topic<strong>?</strong></h2>

MPSI – ENT Case Study

<p>By simulating a real-life Scenario this case study developed to increase the awareness of MPS I, by highlighting familiar symptoms that suggest the possibility of an unfamiliar underlying metabolic disease for ENT specialty.</p>

<h2>Are you interested in knowing more about this topic?</h2>

MPSI – Endocrinology Case Study

<p>By simulating a real-life Scenario this case study developed to increase the awareness of MPS I, by highlighting familiar symptoms that suggest the possibility of an unfamiliar underlying metabolic disease for Endocrinologist specialty.</p>

PRURIGO-NODULARIS

DERMATOLOGY

Mechanism of Prurigo Nodularis Disease

<p>In this comprehensive exploration, we delve into the intricate pathophysiology of Prurigo Nodularis (PN), highlighting the pivotal roles of neuronal sensitization, inflammation, and pruritus. This challenging dermatological condition is characterized by dermatological condition histopathologic alterations, including enhanced hypervascularization, epidermal hyperkeratosis, and dermal fibrosis. Explore the connection between PN and the proinflammatory Th2 cytokine IL-13, shedding light on its binding to IL-4R across various skin components.</p>

<h2>Consensus based on literature supporting clinical presentation and recommendations</h2>
<p style="text-align: center;">Literature Analysis on LOPD Symptoms (Pulmonology): Hierarchy of Evidence</p>

<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
  <tr>
   <td>
    <ul>
     <li>Systemic review and meta-analysis</li>
     <li>Randomized controlled trials</li>
     <li>Observational studies (cohort studies/screening studies)</li>
     <li>Case series studies</li>
     <li>Case series, case reports</li>
     <li>Expert Opinion</li>
    </ul></td>
  </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
  <tr>
   <td>
    <ul>
     <li>4 studies for adult<sup>#</sup>&nbsp;LOPD</li>
     <li>7 studies for pediatric* LOPD and 11 studies for adult<sup>#</sup>&nbsp;LOPD</li>
    </ul></td>
  </tr>
 </tbody>
</table>

<h3 style="text-align: center;">Pulmonology-Specific</h3>
<p style="text-align: center;">Clinical Presentation for Pediatric/Juvenile* and Adult# LOPD Proposed During the First Meeting</p>

<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
  <tr>
   <td>
    <ul>
     <li>&nbsp;Respiratory failure/insufficiency</li>
     <li>&nbsp;Diaphragm weakness</li>
     <li>&nbsp;Dyspnea</li>
     <li>&nbsp;Orthopnea</li>
     <li>&nbsp;Sleep-disordered breathing</li>
    </ul></td>
  </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
  <tr>
   <td style="text-align: center;">High CK/elevated<br>
     LDH, ALT, and AST</td>
  </tr>
 </tbody>
</table>

<h3 style="text-align: center;">Pulmonology-Specific</h3>
<p style="text-align: center;">Diagnostic Algorithm Proposed During the Second Meeting</p>

<h3>Conclusion</h3>
<p>A consensus-based diagnostic algorithm simplifies LOPD diagnosis across specialties</p>
<ul>
 <li>Guides clinicians in the differential diagnosis of LOPD</li>
 <li>&nbsp;Facilitates direct referral for early and accurate diagnosis of LOPD</li>
</ul>

<p><strong>Recommendation</strong><br>
  Testing for Pompe disease must be done if any one specialty-specific symptom plus elevated CK/LDH/ALT/AST or a family history of unexplained muscle weakness are present.</p>

<h2>Conclusion</h2>
<p>*The age of patients with pediatric/juvenile LOPD ranges from 1 to 17 years; #The age of patients with adult LOPD is usually 18 years and above.</p>

Abbreviations

Reference

Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd

POMPE

ACID-SPHINGOMYLENASE-DEFICIENCY-NIEMANN-PICK

How do you know if you or a loved one has ASMD?

<p>This video explains the diagnosis process and its potential delay due to overlap with other conditions.</p>

<h2>Were You Expecting Leukaemia?</h2>
<h3>Think Gaucher Disease</h3>
<h3>A Diagnostic Algorithm for Adults<sup>1</sup></h3>

<h2>Understanding Gaucher Disease Type <sup>1</sup></h2>

<p>GD is the most common LSD caused by a deficiency in glucocerebrosidase enzyme. GD patients may experience 10 years of diagnostic delay.</p>
<p><strong>Test for diagnosis</strong></p>
<ul>
 <li>Enzyme activity test on DBS</li>
 <li>Whole blood sample analysis to confirm diagnosis</li>
</ul>

References

<p>One JLT Building, Level 3, Jumeirah Lake Towers, PO Box 53899, Dubai, UAE For further medical information, please contact: For UAE 800 MEDICAL Toll Free Number. For all Gulf countries +971 565776791 or email:&nbsp;<a href="mailto:medical-information.gulf@sanofi.com."><u>medical-information.gulf@sanofi.com.</u></a></p>
<p>Full prescribing information is available upon request.<br>
  To Report adverse events please call: +971 561747001 or email&nbsp;<a href="mailto:Gulf.Pharmacovigilance@sanofi.com"><u>Gulf.Pharmacovigilance@sanofi.com</u></a><br><a href="http://www.sanofi.com"><u>www.sanofi.com</u></a><br>
  To report any side effect(s): Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC): SFDA call center: 19999 • E-mail:&nbsp;<a href="mailto:npc.drug@sfda.gov.sa"><u>npc.drug@sfda.gov.sa</u></a>&nbsp;• Website:&nbsp;<a href="mailto:https://ade.sfda.gov.sa/"><u>https://ade.sfda.gov.sa/</u></a></p>
<p>Full Prescribing Information is available upon request:<br>
  SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318, Fax: +966-12-663-6191<br>
  For Medical Information, Please contact: +966-12-669-3318,&nbsp;<a href="mailto:ksa.medicalinformation@sanofi.com"><u>ksa.medicalinformation@sanofi.com</u></a><br>
  For Pharmacovigilance, Please contact: +966-54-428-4797,&nbsp;<a href="mailto:ksa_pharmacovigilance@sanofi.com"><u>ksa_pharmacovigilance@sanofi.com</u></a></p>
<p>To report any Product Technical Complaint, please contact SANOFI Quality Department:<br>
  Email:&nbsp;<a href="mailto:quality.greatergulf@Sanofi.com"><u>quality.greatergulf@Sanofi.com</u></a><br><a href="mailto:www.sanofi.com.sa"><u>www.sanofi.com.sa</u></a></p>
<p>MAT-BH-2300002-V2 Mar-25</p>

<h2>Were You Expecting Leukaemia?</h2>
<h3>Think Gaucher Disease</h3>
<h3>A Diagnostic Algorithm for Paediatric Patients<sup>1</sup></h3>

<p>Image adapted from Di Rocco M, et al. Pediatric Blood Cancer 2014. 61(11):1905–1909.</p>

<p>One JLT Building, Level 3, Jumeirah Lake Towers, PO Box 53899, Dubai, UAE For further medical information, please contact: For UAE 800 MEDICAL Toll Free Number. For all Gulf countries +971 565776791 or email:&nbsp;<a href="mailto:medical-information.gulf@sanofi.com."><u>medical-information.gulf@sanofi.com.</u></a></p>
<p>Full prescribing information is available upon request.<br>
  To Report adverse events please call: +971 561747001 or email&nbsp;<a href="mailto:Gulf.Pharmacovigilance@sanofi.com"><u>Gulf.Pharmacovigilance@sanofi.com</u></a><br><a href="http://www.sanofi.com"><u>www.sanofi.com</u></a><br>
  To report any side effect(s): Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC): SFDA call center: 19999 • E-mail:&nbsp;<a href="mailto:npc.drug@sfda.gov.sa"><u>npc.drug@sfda.gov.sa</u></a>&nbsp;• Website:&nbsp;<a href="https://ade.sfda.gov.sa/"><u>https://ade.sfda.gov.sa/</u></a></p>
<p>Full Prescribing Information is available upon request:<br>
  SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318, Fax: +966-12-663-6191<br>
  For Medical Information, Please contact: +966-12-669-3318,&nbsp;<a href="mailto:ksa.medicalinformation@sanofi.com"><u>ksa.medicalinformation@sanofi.com</u></a><br>
  For Pharmacovigilance, Please contact: +966-54-428-4797,&nbsp;<a href="mailto:ksa_pharmacovigilance@sanofi.com"><u>ksa_pharmacovigilance@sanofi.com</u></a></p>
<p>To report any Product Technical Complaint, please contact SANOFI Quality Department:<br>
  Email:&nbsp;<a href="mailto:quality.greatergulf@Sanofi.com"><u>quality.greatergulf@Sanofi.com</u></a><br><a href="http://www.sanofi.com.sa"><u>www.sanofi.com.sa</u></a></p>

Gaucher

GAUCHER

<h3>Fabry Disease Can Result in Substantial Heart Damage<sup>1</sup></h3>
<p>Fabry disease is a rare, progressive, and potentially life-threatening disorder that starts in early childhood and affects men and women.<sup>1-3</sup><br>
  As an X-linked lysosomal storage disorder that is multisystemic, Fabry disease is caused by complete or partial deficiency of the lysosomal enzyme α-GAL A, leading to GL-3 and lyso-GL-3 accumulation that can result in damage to the heart, kidneys, and cerebrovascular system.<sup>2,3</sup></p>

<h3>Early Diagnosis and Management Are Critical as Fabry Disease Can Decrease Life Expectancy Due to Heart and Organ Damage<sup>2,4-6</sup></h3>

<h2>Understanding Fabry Disease</h2>
<p>Worldwide Incidence<sup>7</sup></p>
<p><strong>1 in 40,000</strong></p>
<p>FD is an X-linked disease caused due to deficiency of α-galactosidase A. An average diagnostic delay of 15–18 years is seen in FD.</p>
<p><strong>Test for diagnosis</strong></p>
<ul>
 <li>Enzyme assays to detect α-Gal activity</li>
 <li>Genetic testing to confirm diagnosis</li>
</ul>

<h2>Cardiac Disease is the Leading cause of Death in Patients with Fabry Disease<sup>1</sup></h2>
<h3><strong>Consider Fabry Disease in your Differential Diagnosis when</strong><sup>10</sup>:</h3>
<p><strong>Presentation:</strong>&nbsp;Unexplained HCM and/or LVH, fibrosis in the lateral wall of the left ventricle, low native T1 values, elevated hs-troponin in the absence of acute event<sup>9,11</sup></p>
<p><strong>Family history:</strong>&nbsp;Cardiomyopathy, premature stroke, sudden cardiac death, and renal failure<sup>10,12</sup></p>
<p><strong>ECG:</strong>&nbsp;Bradycardia, short PR interval (young age), AV block (cardiac clinical manifestations in the 3rd decade of life onward), voltage criteria for LVH, ST segment changes, T-wave inversion<sup>8,10</sup></p>

<h3>If you see Unexplained Cardiomyopathy, Consider Fabry Disease.<sup>13</sup></h3>
<p><strong>Cardiologists have the tools to screen for, diagnose, and manage Fabry disease.</strong></p>

<div>
 <table border="1" cellpadding="10" cellspacing="1">
  <tbody>
   <tr>
    <td colspan="2" rowspan="1"><strong>Testing is Straightforward</strong><sup>8,14,15</sup></td>
    <td rowspan="3"><strong>In patients with unexplained HCM, conduct genetic testing that includes the&nbsp;GLA&nbsp;gene.</strong></td>
    <td colspan="1" rowspan="2">Treatment is Available for your Patients with Fabry Disease</td>
   </tr>
   <tr>
    <td><strong>Males</strong></td>
    <td><strong>α-GAL A enzyme assay</strong><br>
      and/or<br><strong>GLA&nbsp;gene sequencing</strong></td>
   </tr>
   <tr>
    <td><strong>Females</strong></td>
    <td>
     <p><strong>GLA&nbsp;gene sequencing</strong></p>
     <p>Affected females may have normal to low enzyme<br>
       activity in plasma or leukocytes; therefore,&nbsp;GLA&nbsp;gene<br>
       sequencing is required to confirm diagnosis in females.</p></td>
    <td><strong>Stabilizing disease progression is an<br>
       important goal.</strong><sup>8</sup></td>
   </tr>
  </tbody>
 </table>
</div>
<p>Damage to cardiac, renal, and cerebrovascular systems can have life-threatening impact. Monitor patients in accordance with published management guidelines and clinicians’ medical expertise.<sup>8</sup></p>

<h2>Discover Fabry Disease:</h2>
<h2>The Role of the Nephrologist</h2>

<h3>Renal Manifestations of Fabry Disease are common and can be Life Threatening.<sup>1,2</sup></h3>
<p>Fabry disease is a rare, progressive, and potentially life-threatening disorder that starts in early childhood and affects men and women.<sup>2-4</sup><br>
  As an X-linked lysosomal storage disorder that is multisystemic, Fabry disease is caused by complete or partial deficiency of the lysosomal enzyme α-GAL A, leading to GL-3<sup>*</sup>&nbsp;and lyso-GL-3 accumulation that can result in damage to the kidneys, heart, and cerebrovascular system.<sup>4</sup></p>

<h3>Early Diagnosis and Management are Critical as Fabry Disease can Decrease Life Expectancy due to Organ Damage.<sup>4-7</sup></h3>

<h2>Understanding Fabry Disease</h2>
<p><strong>Worldwide Incidence<sup>7</sup></strong></p>
<p><strong>1 in 40,000</strong></p>
<p>FD is an X-linked disease caused due to deficiency of α-galactosidase A. An average diagnostic delay of 15–18 years is seen in FD.</p>
<p><strong>Test for diagnosis</strong></p>
<ul>
 <li>Enzyme assays to detect α-Gal activity</li>
 <li>Genetic testing to confirm diagnosis</li>
</ul>

<h2>Renal Manifestations are a Prominent Indication of Fabry Disease and can be Life Threatening<sup>10</sup></h2>
<p><strong>Presentation:</strong>&nbsp;Microalbuminuria, proteinuria, reduced GFR, hematuria (rare), renal cysts (mainly parapelvic), and (in early disease) reduced systemic BP and glomerular hyperfiltration<sup>11</sup></p>
<p><strong>Family history:</strong>&nbsp;Cardiomyopathy, premature stroke, sudden cardiac death, and renal failure<sup>12,13</sup></p>
<p><strong>Laboratory and Biopsy Findings</strong><br><strong>Urinalysis:</strong>&nbsp;“Maltese cross,” “urinary mulberry cells,” biomarkers GL3<sup>*</sup>&nbsp;and lyso-GL3<sup>11</sup><br><strong>Biopsy:</strong>&nbsp;Glomerulosclerosis, vascular lesions, vacuolation, and lysosomal GL3 deposits<sup>11</sup></p>
<p><strong>Rule out Fabry disease in your patients with unexplained CKD.</strong></p>

<div>
 <table border="1" cellpadding="10" cellspacing="1">
  <tbody>
   <tr>
    <td colspan="2" rowspan="1"><strong>Renal Best Practice Screening Recommendations</strong><sup>14</sup></td>
    <td colspan="1"><strong>Testing is Straightforward</strong><sup>9,15</sup></td>
   </tr>
   <tr>
    <td><strong>Males</strong></td>
    <td><strong>Screening&nbsp;MALES&nbsp;&lt;50 years of age with unexplained CKD</strong></td>
    <td colspan="1"><strong>α-GAL A enzyme assay</strong><br>
      and/or<br><strong>GLA&nbsp;gene sequencing</strong></td>
   </tr>
   <tr>
    <td><strong>Females</strong></td>
    <td><strong>Screening&nbsp;FEMALES&nbsp;at any age with unexplained CKD and other symptoms associated with Fabry disease</strong></td>
    <td>
     <p><strong>GLA&nbsp;gene sequencing</strong><br>
       Affected females may have normal-to-low enzyme activity in plasma or leukocytes; therefore, GLA gene sequencing is required to confirm diagnosis in females.</p></td>
   </tr>
  </tbody>
 </table>
</div>
<p>Damage to renal, cardiac, and cerebrovascular systems can have a life-threatening impact. Monitor patients in accordance with published management guidelines and clinicians’ medical expertise.<sup>9</sup></p>
<p><sup>*</sup>GL-3 and Gb3 are interchangeable terms for globotriaosylceramide.</p>

Fabry

FABRY

<h2>Consensus based on literature supporting clinical presentation and recommendations</h2>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
  <tr>
   <td style="text-align: center;">Literature Analysis on LOPD Symptoms (Neurology): Hierarchy of Evidence</td>
  </tr>
 </tbody>
</table>

<div>
 <table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
  <tbody>
   <tr>
    <td style="text-align: center;"><strong>Neurology-Specific Clinical Presentation for Pediatric/Juvenile*and Adult# LOPD Proposed During the First Meeting</strong></td>
   </tr>
  </tbody>
 </table>
 <p>&nbsp;</p>
</div>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
  <tr>
   <td style="text-align: center;"><strong>Pediatric/Juvenile* LOPD</strong></td>
  </tr>
 </tbody>
</table>

<ul>
 <li>Delayed motor milestones</li>
 <li>Low/absent reflexes</li>
 <li>Mild facial muscle weakness</li>
 <li>HyperCKemia/paucisymptomatic</li>
 <li>Negative SMA/DMD</li>
 <li>Shortness of breath at rest or on effort</li>
 <li>Muscle pain and elevated ALT/AST</li>
 <li>Gait abnormalities</li>
 <li>Scoliosis/scapular winging</li>
 <li>Disproportional weakness of the neck flexors and difficulty in raising the head</li>
</ul>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
  <tr>
   <td style="text-align: center;"><strong>Adult# LOPD</strong></td>
  </tr>
 </tbody>
</table>

<ul>
 <li>LGMW</li>
 <li>Swallowing difficulties</li>
 <li>Frequent falls</li>
 <li>Difficulty chewing/jaw muscle fatigue</li>
 <li>Difficulty in walking and climbing stairs</li>
 <li>Double-seronegative MG</li>
 <li>Muscle pain and elevated ALT/AST</li>
 <li>Gait abnormalities</li>
 <li>HyperCKemia/paucisymptomatic</li>
 <li>Unexplained myopathy</li>
 <li>Scoliosis/scapular winging</li>
</ul>

<p>High CK/elevated LDH,<br>
  ALT,and AST</p>

<p style="text-align: center;">Family history of unexplained<br>
  muscle weakness or respiratory<br>
  failure</p>

<div>
 <table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
  <tbody>
   <tr>
    <td style="text-align: center; width: 100%; height: 100%;"><strong>Proposed Diagnostic Algorithm for Neurologists During the Second Meeting</strong></td>
   </tr>
  </tbody>
 </table>
 <p>&nbsp;</p>
</div>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
  <tr>
   <td style="text-align: center;">
    <p><b>Recommendation</b></p>
    <p>Testing for Pompe disease must be done if any one specialty-specific symptom plus elevated CK/LDH/ALT/AST or a family history of unexplained muscle weakness is present.</p></td>
  </tr>
 </tbody>
</table>

<p><sup>*</sup>The age of patients with pediatric/juvenile LOPD ranges from 1 to 17 years;&nbsp;<sup>#</sup>The age of patients with adult LOPD is usually 18 years and above.</p>

Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at <strong>{email}</strong> to confirm your account you can request a new one below. If you don't see it, you may need to <strong>check your spam</strong> folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you <strong>specific and relevant content</strong>

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, <b>Fotolia.de</b>, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

<strong>Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.</strong><br></br><br></br><br></br>

<strong>Please follow these steps to complete your registration:</strong><br></br><br></br>

<strong>Would you like to receive future text messages about Beyfortus updates?</strong>

<strong>Sanofi is here to help support your patients, their families, and caregivers.</strong><br></br><br></br>For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text.<br></br><br></br><strong>All fields are required.</strong>

Would you like to learn more about Beyfortus<sup>®</sup> (nirsevimab-alip) 50 mg and 100 mg injection?<br></br>Leave us your contact details, and a Sanofi representative will be in touch.<br></br><br></br><strong>All fields are required.</strong>

<strong>Would you also like to receive future messages and updates about Beyfortus?</strong>

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local ALTUVIIIO representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local QFITLIA representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required (unless otherwise specified).</strong>

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. <br></br>Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles